EGFR and non-small cell lung carcinoma: MSK-LX29 tumor [29] was derived from the patient with EGFR mutant NSCLC who developed resistance after 3 months of erlotinib treatment with an acquired MET amplification and had the highest TWIST1 expression (Fig. 1C).